Scientists Refine and Develop New Strategies to Target Bone Metastases
ran across this article, google title above
Another agent, called cabozantinib, “has had a spectacular result” in a phase II randomized trial of advanced prostate cancer patients, says Smith, who took part in the study. The phase III COMET-1 is currently testing the oral targeted agent in men with CRPC who have already been treated with the FDA-approved androgen-receptor pathway agents abiraterone acetate and enzalutamide.
Cabozantinib inhibits the MET tyrosine kinase as well as vascular endothelial growth factor receptor 2 (VEGFR2). Seventy-two percent of the 171 men in the phase II trial had tumor shrinkage in areas excluding the bone and 68% had improvements in bone metastases. The striking improvements in patients’ bone scans haven’t been seen before, Smith says. Patients also had relief from the pain associated with these metastases—67% showed improvement in pain.
“The bone metastases improvement was unexpected, but it is explainable,” Smith says. VEGFR is involved in bone remodeling, prostate tumor growth, and tumor-bone interaction.